2. Inflammation/Immunology

Inflammation/Immunology

Inflammation/Immunology

Related Products

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-N0565C
    Doxycycline calcium 94088-85-4 98%
    Doxycycline calcium is an orally active highly lipophilic, tissue-permeable MMP inhibitor with broad-spectrum antibacterial activity. Doxycycline calcium is also a semi-synthetic antibiotic with chelating properties, which blocks bacterial protein synthesis and inhibits extracellular matrix degradation through interactions with zinc and calcium atoms. Doxycycline calcium also inhibits mitochondrial biogenesis, translation, and the expression of respiratory chain proteins. Doxycycline calcium induces apoptosis, inhibits autophagy and EMT, downregulates stem cell markers, and activates the PI3K-AKT pathway, thereby effectively inhibiting the viability and proliferation of cancer cells such as breast cancer cells. Doxycycline calcium also promotes the survival and self-renewal of embryonic stem cells and neural stem cells, and reduces the frequency of medium changes in culture. Doxycycline calcium has been applied in studies related to breast cancer, prostate cancer, bladder cancer, and other cancers.
    Doxycycline calcium
  • HY-P1698B
    Reltecimod TFA 99.78%
    Reltecimod (AB-103) TFA is a T-cell-specific surface glycoprotein CD28 (TP44) antagonist. Reltecimod TFA has beneficial effects against different bacterial infections, their exotoxins and endotoxins, and ionizing radiation. Reltecimod TFA modulates the inflammatory response by targeting and attenuating the critical CD28/B7-2 co-stimulatory pathway, without inhibiting it. Reltecimod TFA can be used to research necrotizing soft-tissue infections (NSTIs).
    Reltecimod TFA
  • HY-P2519A
    Protease-Activated Receptor-3 (PAR-3) (1-6), human TFA 99.86%
    Protease-Activated Receptor-3 (PAR-3) (1-6), human TFA is a proteinase-activated receptor (PAR-3) agonist peptide.
    Protease-Activated Receptor-3 (PAR-3) (1-6), human TFA
  • HY-P99122
    Anti-Mouse CD209b Antibody (22D1) 99.00%
    Anti-Mouse CD209b Antibody (22D1) is an anti-mouse CD209b IgG1 antibody inhibitor derived from the host Armenian Hamster. Anti-Mouse CD209b Antibody (22D1) can block SIGN-R1. Anti-Mouse CD209b Antibody (22D1) can be used for the researches of infection, inflammation and immunology, such as toxoplasma infection and pneumonia.
    Anti-Mouse CD209b Antibody (22D1)
  • HY-P99310
    Perakizumab 89957-37-9 99.79%
    Perakizumab (RG4934) is a humanized IgG1κ monoclonal antibody against IL-17A (Interleukin Related). Perakizumab can be uesd for the research of autoimmune diseases, such as psoriatic arthritis.
    Perakizumab
  • HY-P99323
    Timolumab 1073538-99-4 98.56%
    Timolumab (BTT1023 ), a recombinant fully human monoclonal antibody that specifically binds VAP-1. Timolumab (BTT1023 ) could be used in the study of chronic inflammatory diseases.
    Timolumab
  • HY-P99515
    Xeligekimab 2382921-73-3
    Xeligekimab (GR 1501) is an anti-human interleukin 17A (IL-17A) humanized monoclonal antibody. Xeligekimab inhibits the pro-inflammatory cascade. Xeligekimab can be used for the research of inflammatory disease, such as radiographic axial spondyloarthritis.
    Xeligekimab
  • HY-P99606
    Cirevetmab 2473240-98-9 ≥99.0%
    Cirevetmab (ZTS-00521426) is an immunoglobulin G2-kappa, Canis lupus familiaris TGFB1 caninized monoclonal antibody. Cirevetmab is an immunomodulator.
    Cirevetmab
  • HY-P99664
    Inolimomab 152981-31-2 98.78%
    Inolimomab is an anti-interleukin-2 receptor (IL-2R) α chain monoclonal antibody. Inolimomab improves the survival rate in the early research of treating acute graft-versus-host disease (aGVHD).
    Inolimomab
  • HY-P99782
    Opinercept 2055118-96-0
    Opinercept is a recombinant fusion protein comprising an TNFRSF1B fused to a human IgG1 Fc. Opinercept is a tumor necrosis factor-alpha (TNF-alpha) inhibitor. Opinercept can be used for the research of rheumatoid arthritis (RA).
    Opinercept
  • HY-P99855
    Divozilimab 2254061-60-2 99.63%
    Divozilimab (BCD-132) is a humanised monoclonal antibody against CD20 (CD20). Divozilimab can be used for multiple sclerosis research.
    Divozilimab
  • HY-P99913
    Eflapegrastim 1384099-30-2
    Eflapegrastim is a composite protein consisting of a genetically modified granulocyte-colony stimulating factor (GCSF) molecule linked via a chemical bond to an IgG4 Fc fragment (LAPS-carrier). Eflapegrastim targets to G-CSF receptor (c-Fms). Eflapegrastim stimulates proliferation and differentiation of neutrophil progenitor cells and maintains stable numbers of mature and functional neutrophils. Eflapegrastim also shortens the duration of neutropenia.
    Eflapegrastim
  • HY-103671A
    IPN60090 dihydrochloride 2102101-72-2 99.68%
    IPN-60090 dihydrochloride is an orally active and highly selective inhibitor of glutaminase 1 (GLS1; IC50=31 nM), with no activity observed against GLS-2. IPN-60090 dihydrochloride exhibits excellent physicochemical and pharmacokinetic properties in vivo. IPN-60090 dihydrochloride can be used for solid tumors research, such as lung and ovarian cancers.
    IPN60090 dihydrochloride
  • HY-112243A
    Cimpuciclib tosylate 2408872-84-2 99.65%
    Cimpuciclib tosylate is a selective CDK4 inhibitor (IC50: 0.49 nM) that has anti-tumor activity.
    Cimpuciclib tosylate
  • HY-120878A
    (R,R)-CXCR2-IN-2 1838123-22-0 99.37%
    (R,R)-CXCR2-IN-2 (compound 67), diastereoisomer of CXCR2-IN-2 (compound 68) (HY-120878), is a CXCR2 antagonist with a pIC50 of 9 and 6.8 in the Tango assay and d in the HWB Gro-α induced CD11b expression assay, respectively.
    (R,R)-CXCR2-IN-2
  • HY-136978A
    OP-5244 sodium 99.87%
    OP-5244 sodium is a potent and orally active inhibitor of CD73, with an IC50 of 0.25 nM. OP-5244 sodium reverses immunosuppression through blocking of adenosine production, and has the potential for the cancer research.
    OP-5244 sodium
  • HY-137451A
    (E/Z)-Sivopixant 1640808-39-4 98.64%
    (E/Z)-Sivopixant ((E/Z)-S-600918) is a potent P2X3 receptor antagonist with an IC50 of 4 nM. (E/Z)-Sivopixant can be used for respiratory diseases research.
    (E/Z)-Sivopixant
  • HY-144168A
    STING agonist-8 dihydrochloride 98%
    STING agonist-8 dihydrochloride (compound 5-AB) is a potent STING agonist with an EC50 of 27 nM in THP1-Dual KI-hSTING-R232 cells.
    STING agonist-8 dihydrochloride
  • HY-145723C
    MAX-40279 hemiadipate 2388506-44-1 99.26%
    MAX-40279 hemiadipate is a dual and orally active inhibitor of FLT3 kinase and FGFR kinase. MAX-40279 hemiadipate is also effective against the FLT3 mutants such as FLT3D835Y, suggesting that it can overcome resistance to Quizartinib (HY-13001) and Sorafenib (HY-10201). MAX-40279 hemiadipate inhibits NDRG1 phosphorylation at Ser330 and suppresses endothelial-to-mesenchymal transition (EndMT). MAX-40279 hemiadipate can be used for the research of acute myelogenous leukemia (AML).
    MAX-40279 hemiadipate
  • HY-P990046
    Tuparstobart 2649466-03-3
    Tuparstobart (Incagn-02385) is an IgG1κ antibody targeting LAG-3. LAG-3 is an immune checkpoint receptor protein mainly expressed on activated T cells, NK cells, B cells and plasmacytoid dendritic cells.
    Tuparstobart
Cat. No. Product Name / Synonyms Application Reactivity